Phase III Study of Sodium Oligo-mannurarate (GV-971) Capsule on Mild to Moderate Alzheimer's Disease

Trial Profile

Phase III Study of Sodium Oligo-mannurarate (GV-971) Capsule on Mild to Moderate Alzheimer's Disease

Recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Aug 2016

At a glance

  • Drugs Sodium oligomannurarate (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Sponsors Shanghai Green Valley Pharmaceutical
  • Most Recent Events

    • 08 Aug 2016 Planned End Date changed from 1 May 2017 to 1 Oct 2017.
    • 08 Aug 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Sep 2017.
    • 21 Nov 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top